Phase 1/2a Study of Ropinirole Hydrochloride Extended-Release Tablets in Patients with Amyotrophic Lateral Sclerosis (ALS) Phase 1/2a Study of RopiniroleHydrochloride Extended-Release Tablets in Patients with Amyotrophic La ...
Phase 1/2a, Double-blind, Placebo-controlled Study with an Open-label Extension of Ropinirole Hydrochloride Extended-Release Tablets-Explorative Assessment of the Safety, Tolerability, and Efficacy after Oral Treatment in Patients with Amyotrophic Lateral Sclerosis (ALS)- Phase 1/2a, Double-blind, Placebo-controlled Study with an Open-label Extension of RopiniroleHydroch ...
amyotrophic lateral sclerosis (ALS)
Intervention type:DRUG. Intervention1:Requip CR tablets, Dose form:SUSTAINED-RELEASE TABLET, Route of administration:ORAL, intended dose regimen:Once daily ropinirole hydrochloride extended-release tablet with dose-escalation tolerable from 2mg to 16mg for 24 weeks (Interventions). Control intervention1:Placebo, Dose form:SUSTAINED-RELEASE TABLET, Route of administration:ORAL, Intended dose regimen:Once daily placebo tablet with dose-escalation tolerable from 2mg to 16mg for 24 weeks (Interventions). Intervention type:DRUG. Intervention1:Requip CRtablets, Dose form:SUSTAINED-RELEASE TABLET, Route of ...